Posted by Michael Wonder on 06 Sep 2022
Boston Scientific receives FDA approval for expanded labelling of Watchman FLX LAAC device for dual anti-platelet therapy as post-procedural medication option
6 September 2022 - Watchman FLX now the only LAAC technology in the United States that allows for either dual anti-platelet therapy or oral anti-coagulant immediately following implantation.
Boston Scientific has received U.S. FDA approval to expand the instructions for use labelling for the current-generation Watchman FLX left atrial appendage closure device to include a 45 day dual anti-platelet therapy option as an alternative to 45-day oral anti-coagulation plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation.
